- A terahertz accelerator was proposed as an experimental platform for low-energy nuclear-reaction research by firing deuterons into palladium or nickel crystals, with suggestions to defocus the beam onto thin films to improve heat transfer and reaction yield.  
- The DNA-synthesis industry was criticized for withholding cost-curve and road-mapping data; consortium members reportedly avoid even mentioning “PCR” and maintain “obsessively paranoid” control practices that stifle open collaboration.  
- Twist Bioscience raised $50 M for DNA data-storage and drug-discovery applications, while DNA Script secured an additional $5.5 M in grants, bringing its total funding to $24 M for enzymatic DNA-synthesis technology licensed from Dynamic Combinatorial Chemistry.  
- An open-source, MTA-free E. coli → P. pastoris shuttle vector for chromosomal integration is under active development, with plans to extend the toolkit to S. cerevisiae and non-integrative E. coli vectors; progress is tracked at https://wiki.realvegancheese.org.  
- Participants warned about chronic phthalate and flame-retardant off-gassing from conventional mattresses and infant clothing, advocating latex/wool replacements or fully encapsulating beds with waterproof covers.  
- Export-control discussion clarified that most DNA-synthesis hardware is not on the U.S. Commerce Control List, but broader “biological manufacturing equipment,” 5-axis motion systems, and certain genetic elements can face restrictions.  
- A commercial AAV vector over-expressing human follistatin (Vector Biolabs AAV-209350) was identified as a ready-made backbone for high-titer viral production aimed at muscular-dystrophy gene therapy and potential muscle enhancement.  
- George Church’s Boing Boing interview and Andrew Hessel’s Medium post on the Human Genome Project-Write were circulated, with Hessel projecting a fully synthetic human genome by 2050–2060.  
- The group debated AAV-mediated follistatin over-expression versus recombinant-protein injection for muscle enhancement, weighing viral self-amplification and low-dose potential against the need for 10^13–10^14 particles, neutralizing immunity, and the cost of repeat dosing.